AI assistant
Episurf — Share Issue/Capital Change 2018
Jun 29, 2018
3157_rns_2018-06-29_8e723e90-5011-49f9-8bc7-6e362f5d2141.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Change in number of shares and votes in Episurf Medical
On the behalf of shareholders in Episurf Medical AB (NASDAQ: EPIS B), conversions of class A shares to B shares were carried out during June in accordance with theArticles ofAssociation. Through the conversions, the number ofA shares have decreased by 558 and the number of B shares have increased by the same amount.
Episurf Medical AB has also performed conversion of convertible bonds issued under the financing agreement published February 23, 2018. The number of convertibles converted in June was 20. The number of convertibles remaining during the first tranche for future conversion is 120. Through the conversion, the number of shares and votes increased by 204,639. The terms of the convertibles are published on Episurf Medical AB's website.
The total number of shares amounts to 30,753,576, of which 5,257,078 areA shares and 25,496,498 are B shares. The total number of votes after the conversions amounts to 41,267,732.
For more information, please contact:
Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: [email protected]
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical's Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11.00 CEST on 29 June 2018.